Contraceptive Data Repository For Teratogenic Drug Patients Urged By FDA Panel
Executive Summary
An updatable web-based repository of information on contraceptives would remedy the shortcomings of the current system, where information differs across drugs and is only as current as labeling, several members of the Drug Safety and Risk Management Advisory Committee note during a meeting on teratogenic risk management.
You may also be interested in...
Teratogenic Drugs Pose Little Risk To Partners Of Male Patients, FDA Panel Says
There is little to no evidence that a teratogenic drug would pass from a man to his female partner at a high enough level to endanger a fetus, the Drug Safety and Risk Management Advisory Committee tells FDA.
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Prescriber training courses to be provided through continuing medical education venues are to be available by March 1, 2013. Changes from the draft are subtle, but indicate FDA’s focus on preventing incorrect use of the high-dosage narcotics and protecting patients.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.